The specialized resource offers patients with
rare mutations or fusions in non-small cell lung cancer (NSCLC) and
their caregivers access to treatment information, informative
webinars, the latest scientific news, and a supportive
community
WASHINGTON, June 28,
2022 /PRNewswire/ -- LUNGevity Foundation, the
nation's leading lung cancer-focused nonprofit organization, has
launched the Rare Mutations and Fusions Lung Cancer Patient
Gateway. This new resource joins a suite of Patient
Gateways for lung cancer survivors that present relevant
information tailored to their specific subtype. The Rare Mutations
and Fusions Patient Gateway will allow survivors with non-small
cell lung cancer who have gene mutations or fusions such as ROS1,
MET, RET, NTRK, BRAF, and others to locate specialists and
resources more easily. The Patient Gateway also features
information on treatment options and the ability to connect with a
community of fellow survivors and their caregivers.
Targeted therapies exist for nine DNA-based alterations, or
biomarkers, in non-small cell lung cancer. Of those nine mutations,
ROS1, MET, RET, NTRK, and BRAF are considered rare, with an
occurrence rate of 4% or less in patients with NSCLC. "Thanks to
research in non-small cell lung cancer, more biomarkers and
targeted therapies to treat them have been discovered," said
Amy Moore, PhD, vice president,
global engagement and patient partnerships at LUNGevity Foundation.
"You often hear about the more common NSCLC biomarkers, such as
ALK, EGFR, or KRAS. Our Rare Mutations and Fusions Lung Cancer
Patient Gateway caters to patients living with cancer driven by
lesser-known mutations. It is important to give these patients and
their caregivers a dedicated space to learn about treatment options
and access information related to their specific cancer type."
The Rare Mutations and Fusions Patient Gateway is a
user-friendly and easily accessible information portal that offers
the latest medical updates and practical resources for patients and
their caregivers. The Gateway, available at
rare-mutations.lungevity.org, provides visitors with information
about biomarker testing and the targeted therapies available for
each mutation type. Visitors can also find a specialist based on
individualized search criteria, join a variety of patient and
caregiver communities, explore clinical trial options, and read
up-to-the-minute, curated news and trends. Each individual Gateway
features expert webinars and blogs, patient and caregiver stories,
and quarterly newsletters.
The Rare Mutations and Fusions Patient Gateway joins the EGFR,
KRAS, ALK, and non-small cell lung cancer (NSCLC) platforms on
gateway.lungevity.org. A Gateway dedicated to small cell lung
cancer is launching later this year.
The Rare Mutations and Fusions Patient Gateway is supported by a
generous sponsorship from AstraZeneca, Bayer Healthcare, Blueprint,
Janssen, Lilly, Novartis, and Takeda Oncology.
About LUNGevity
Foundation
LUNGevity Foundation is the nation's leading lung cancer
organization focused on improving outcomes for people with lung
cancer through research, education, policy initiatives, and support
and engagement for patients, survivors, and caregivers. LUNGevity
seeks to make an immediate impact on quality of life and
survivorship for everyone touched by the disease—while promoting
health equity by addressing disparities throughout the care
continuum. LUNGevity works tirelessly to advance research into
early detection and more effective treatments, provide information
and educational tools to empower patients and their caregivers,
promote impactful public policy initiatives, and amplify the
patient voice through research and engagement. The organization
provides an active community for patients and survivors—and those
who help them live better and longer lives.
Comprehensive resources include a medically vetted and
patient-centric website, a toll-free HELPLine for support, the
International Lung Cancer Survivorship Conference, and an
easy-to-use Clinical Trial Finder, among other tools. All of these
programs are to achieve our vision—a world where no one dies of
lung cancer. LUNGevity Foundation is proud to be a four-star
Charity Navigator organization.
About Lung Cancer in the US
- About 1 in 17 Americans will be diagnosed with lung cancer in
their lifetime.
- More than 236,000 people in the US will be diagnosed with lung
cancer this year.
- About 60%-65% of all new lung cancer diagnoses are among people
who have never smoked or are former smokers.
- Lung cancer takes more lives in the
United States than the next two deadliest cancers
(colorectal and pancreatic) combined.
- Only about 23% of all people diagnosed with lung cancer in
the United States will survive 5
years or more, BUT if it is caught before it spreads, the chance of
5-year survival improves dramatically.
Please visit LUNGevity.org to learn more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lungevity-launches-new-rare-mutations-and-fusions-patient-gateway-301576548.html
SOURCE LUNGevity Foundation